Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04867187
Recruiting Not applicable

rTMS Efficacy Coupled With Mirror Therapy

NCT04867187 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-10-27
Last updated
2026-05-08

Condition(s) studied

Neuropathic Pain

Investigational drug(s) / intervention(s)

Repetitive transcranial magnetic stimulation (rTMS)Mirror therapy using virtual realityMirror therapy using sham mirror

Repetitive transcranial magnetic stimulation (rTMS): 20 minutes of high frequency (20Hz) rTMS.

Mirror therapy using virtual reality: active mirror-based therapy

Mirror therapy using sham mirror: 20 minutes of sham mirror-based therapy

Study summary

Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS.The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical symptoms typical of neuropathic pain * Refractory to drug therapies * Lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on Visual Analog Scale, VAS) and a stable pain treatment since 1month at least * Having right to health benefits Exclusion Criteria: * Ferromagnetic components and implanted microprocessors (i.e. cochlear implants) * Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment. * Any other contraindications to MRI scanner (e.g., claustrophobia, etc.).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Hôpital Neurologique Pierre Wertheimer Bron France Not Yet Recruiting
Centre Hospitalier Universitaire de Saint-Etienne Saint-Etienne France Recruiting

More Centre Hospitalier Universitaire de Saint Etienne trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04867187 on ClinicalTrials.gov ↗ ← All trials in France